Exelixis Competitors
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|
| MRK | Merck | Outperform |
2
|
$128.80 | $130.51 | 11.02% | 11 | $327.32B |
| ROG | Roche Holding | Hold |
16
|
CHF220.60 | CHF307.83 | 23.53% | 9 | CHF178.03B |
| PFE | Pfizer | Outperform |
2
|
$27.18 | $32.87 | 12.21% | 6 | $153.91B |
| REGN | Regeneron Pharmaceuticals | Outperform |
2
|
$903.48 | $961.26 | 16.22% | 8 | $96.09B |
| BMY | Bristol-Myers Squibb | Hold |
2
|
$44.21 | $58.15 | 22.14% | 10 | $89.07B |
| BAYN | Bayer | Hold |
5
|
27.35€ | 45.15€ | 9.69% | 4 | 26.87€B |
| 4523 | Eisai | Outperform |
18
|
¥6.55k | ¥9.58k | 28.26% | 0 | ¥1.86T |
| INCY | Incyte | Outperform |
9
|
$52.94 | $77.05 | 45.83% | 8 | $11.89B |
| JAZZ | Jazz Pharmaceuticals | Outperform |
14
|
$110.31 | $188.32 | 69.98% | 4 | $6.88B |
| IONS | Ionis Pharmaceuticals | Outperform |
9
|
$43.01 | $55.60 | 39.97% | 3 | $6.02B |
| BPMC | Blueprint Medicines | Outperform |
6
|
$94.86 | $85.71 | 5.42% | 5 | $5.74B |